Click on their name to send an email.
Andre Baron, M.S., Ph.D., M.P.H.
Dr. Baron received his B.A. in Biology from Western Connecticut State University, M.S. in Developmental Biology from Adelphi University, and Ph.D. in Cell Biology from Case Western Reserve University, after which he continued his training as a postdoctoral fellow in Molecular Biology and Biochemistry at the Mayo Clinic. Later, as a Research Associate/Assistant Professor at the Mayo Clinic, he was awarded simultaneously a KO7 Preventive Oncology Career Development Award, RO3, and R21 research grant from the National Cancer Institute to study soluble epidermal growth factor receptor (sEGFR) isoforms as tumor biomarkers, and to pursue an M.P.H. in Epidemiology from the University of Minnesota. Through his translational research, Dr. Baron discovered serum sEGFR and demonstrated that this biomarker may have clinical utility for the risk assessment, screening, diagnosis, prognosis, and theragnosis of breast, ovarian, and lung cancer. Dr. Baron’s laboratory is actively exploring further each of these potential uses for sEGFR and also is engaged in the discovery and development of novel cancer biomarkers using modern proteomic methods. He has co-authored several book chapters and his articles have appeared in publications such as: Journal of Cell Biology, Cell Motility and the Cytoskeleton, Biology of the Cell, Journal of Cell Science, Protoplasma, Hybridoma and Hybridomics, Journal of Immunological Methods, Cancer Epidemiology Biomarkers and Prevention, The Female Patient, Journal Clinical Ligand Assay, Annals of Oncology, Cancer Research, Nature Clinical Practice Oncology, and Patient Care. Dr. Baron holds a joint appointment in the College of Public Health, Department of Epidemiology and the College of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. He serves as Course Director for Molecular Epidemiology, Cancer Prevention and Control, and Public Health Biology; and also teaches in a number of additional Graduate School courses including: Biology and Therapy of Cancer, Advanced Toxicology, and Cancer Epidemiology. Dr. Baron is recognized internationally for his work on sEGFR as a biomarker of ovarian cancer and has served as a member of peer review panels for the National Cancer Institute (Specialized Programs of Research Excellence in Ovarian & Gynecologic Cancers), American Cancer Society (Canary Fund, Postdoctoral Fellowship Program in the Early Detection of Cancer), and U.S. Army Medical Research and Material Command, Department of Defense (Ovarian Cancer Research Program in Cell Biology & Immunology). He also is a member of the Markey Cancer Center Biospecimens Core Program Steering Committee, Marty Driesler Lung Cancer Program Executive Committee, Gastrointestinal Cancer Clinical Care and Research Team, Lung Cancer Clinical Care and Research Team, and Cancer Prevention and Control Program.